156 results
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
12 Jul 22
Agios Appoints Brian Goff as Chief Executive Officer
4:14pm
,” said Dr. Fouse. “The time is right to evolve our leadership and deepen our genetically defined disease skill set to further drive our ability … portfolio.
“At every step of Agios’ journey, our board and leadership team give careful consideration to what should come next for the company
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
6 Dec 22
Agios Appoints Tsveta Milanova as Chief Commercial Officer
7:37am
executive officer at Agios. “Her leadership and strategic insights have contributed to the exponential growth of leading global biopharmaceutical … and business development, oncology portfolio management and commercial leadership. She seamlessly led the transition of the company’s oncology assets
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
19 Sep 22
Agios Appoints Cecilia Jones as Chief Financial Officer
7:08am
Pharmaceuticals.
“With more than two decades of experience in financial leadership roles with leading biopharmaceutical companies, including most … recently as chief financial officer of a rare disease company, we are thrilled to welcome Cecilia as a strategic member of our leadership team
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
13 Jan 14
Regulation FD Disclosure
12:00am
leadership in the field of cancer
metabolism and inborn errors of
metabolism
Agios Pharmaceuticals
CONFIDENTIAL
A leader in field of dysregulated … cellular metabolism –
breakthrough area for drug discovery and development
Biomarkers for patient selection for every program
Agios leadership team
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
2 May 19
Agios Reports Business Highlights and First Quarter 2019 Financial Results
7:24am
2proof-of-concept study for mitapivat in thalassemia.
Announced two newly created commercial leadership roles to support the commercialization … leadership, was promoted to senior vice president, U.S. commercial and global marketing. In addition, a search is underway for the role of senior vice
8-K
EX-99.1
09ie3a4 9g7awx9zo
21 Dec 20
Regulation FD Disclosure
7:04am
8-K
EX-99.1
wqpb 2l2cny
8 Sep 20
Agios Appoints Jonathan Biller as Chief Financial Officer, Head of Legal and Corporate Affairs
4:09pm
DEFA14A
EX-99.1
qtpdw92
21 Dec 20
Additional proxy soliciting materials
7:10am
8-K
EX-99.1
aot94l7h
29 Jun 18
Agios and CStone Pharmaceuticals Announce Exclusive Collaboration and License
4:06pm
DEFA14A
lyuclchwo8t ftdj4cm
21 Dec 20
Additional proxy soliciting materials
5:21pm
8-K
EX-99.1
iq4a4t53
4 May 23
Agios Reports Business Highlights and First Quarter 2023 Financial Results
7:03am
8-K
EX-99.1
wt3jy
6 Mar 14
Agios Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results
12:00am
8-K
EX-99.1
ryrdy28m9vmol
3 Aug 23
Agios Reports Business Highlights and Second Quarter 2023 Financial Results
6:38am
8-K
EX-99.1
7gu matffzhj
3 Nov 22
Agios Reports Business Highlights and Third Quarter 2022 Financial Results
7:02am
8-K
EX-99.1
63hi8otgtquidhhaw9sx
11 Jan 21
Agios Highlights 2021 Milestones to Accelerate and Expand Its Genetically Defined Disease Portfolio and Drive Near- and Long-Term Value Creation
7:14am
8-K
EX-99.1
bctgiv wp8yd8mvkwbw
5 Nov 20
Agios Reports Business Highlights and Third Quarter 2020 Financial Results
7:32am
DEFA14A
3zzkzp np1w
11 Jan 21
Additional proxy soliciting materials
7:17am
8-K
EX-99.1
yj1s0db4ff dc6zkmtrx
11 Dec 14
Agios Pharmaceuticals Announces Pricing of $220 Million Public Offering of Common Stock
12:00am